Management of Overactive Bladder in Older Women

Overactive BladderUrinary IncontinenceUrinary Tract Infections (UTI)

Overactive bladder symptoms after midurethral sling surgery in women: Risk factors and management

Neurourol Urodyn.

Marcelissen T, Van Kerrebroeck P

doi: 10.1002/nau.23328.

Overactive Bladder

Beyond the bladder: poor sleep in women with overactive bladder syndrome

Am J Obstet Gynecol.

Savoie MB, Lee KA, Subak LL, Hernandez C, Schembri M, Fung CH, Grady D, Huang AJ

doi: 10.1016/j.ajog.2019.12.005.

Overactive Bladder

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Neurourol Urodyn.

Mueller ER, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Stoelzel M, Yoon SJ, Al-Shukri S, Rechberger T, Gratzke C

doi: 10.1002/nau.23919.

Overactive Bladder

Association between overactive bladder treatment and falls among older adults

Neurourol Urodyn.

Jayadevappa R, Chhatre S, Newman DK, Schwartz JS, Wein AJ

doi: 10.1002/nau.23719.

Lower Urinary Tract SymptomsOveractive Bladder

Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study

Int Neurourol J.

Choi H, Bae JH, Oh CY, Jeong SJ, Ko WJ, Choi JB, Seo JT, Lee DH, Kim JC, Lee KW, Kim YH

doi: 10.5213/inj.1834982.491.

Overactive BladderMenopause

Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause

Eur J Obstet Gynecol Reprod Biol.

Matarazzo MG, Caruso S, Giunta G, Valenti G, Sarpietro G, Cianci A

doi: 10.1016/j.ejogrb.2018.01.002.

Overactive Bladder

Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months

Int Braz J Urol.

Vecchioli-Scaldazza C, Morosetti C

doi: 10.1590/

Overactive BladderUrinary Incontinence

Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms

Gynecol Endocrinol.

Schiavi MC, Zullo MA, Faiano P, D'Oria O, Prata G, Colagiovanni V, Giannini A, Di Tucci C, Perniola G, Di Donato V, Monti M, Muzii L, Benedetti Panici P

doi: 10.1080/

Overactive Bladder

Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand?

Eur Urol Focus.

Marcelissen T, Rashid T, Antunes Lopes T, Delongchamps NB, Geavlete B, Rieken M, Cornu JN, Rahnama'i MS

doi: 10.1016/j.euf.2018.03.011.

Related content

Overactive bladder symptoms after midurethral sling surgery in women: Risk factors and management

Beyond the bladder: poor sleep in women with overactive bladder syndrome

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Association between overactive bladder treatment and falls among older adults

Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study

Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause

Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months

Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms

Oral Pharmacologic Management of Overactive Bladder Syndrome: Where Do We Stand?